Erasca Inc (ERAS)

$3.43 +0.04 (1.18%)
Market Cap 961.78M
Revenue (ttm) 0.00
Net Income (ttm) -161.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,231,300
Avg Vol 1,910,744
Day's Range N/A - N/A
Shares Out 283.71M
Stochastic %K 23%
Beta 1.16
Analysts Strong Sell
Price Target $4.29

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 465 6511
Address:
3115 Merryfield Row, Suite 300, San Diego, United States
1SwingSensei
1SwingSensei Dec. 22 at 3:51 PM
$ERAS I'm liking the melt up of several stocks
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 17 at 11:35 PM
$ASNS $BEAT $ERAS $TLRY $18-$20 coming for TLRY… The Good News is I rarely miss!!
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 17 at 9:44 PM
$ASNS banked $ERAS Banking $BEAT Banked $TLRY Loaded… Avg $10.75, this is setting up for a major rally.. weak hands are out! PT $18-$20
0 · Reply
TravisA9
TravisA9 Dec. 17 at 6:06 PM
$ERAS Got back in a few weeks ago around $3.20 with some size. Clear breakout. I think we close gap from 12/2022, let’s see.
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 16 at 2:58 PM
$BDRX NHOD will send this to $9… Watching closely $ERAS looking good…. over $3.80 and we see mid $4’s
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 15 at 7:52 PM
$ERAS Adding more here… Beautiful swing set up!!!
1 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 15 at 4:05 PM
$ERAS I’m in for a swing… PT1 $4.50
0 · Reply
prominence687
prominence687 Dec. 15 at 1:52 PM
$ERAS is looking primed!
0 · Reply
DavyDaveCharts
DavyDaveCharts Dec. 14 at 8:35 PM
$ERAS peekaboo
0 · Reply
vu_jade
vu_jade Dec. 13 at 10:21 PM
$ERAS yup
0 · Reply
Latest News on ERAS
Erasca to Present at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 9:08 AM EST - 4 weeks ago

Erasca to Present at the 8th Annual Evercore Healthcare Conference

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Nov 12, 2025, 4:01 PM EST - 6 weeks ago

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Nov 6, 2025, 8:00 AM EST - 6 weeks ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Erasca to Present at Upcoming Conferences in November

Nov 4, 2025, 8:00 AM EST - 7 weeks ago

Erasca to Present at Upcoming Conferences in November

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Jun 2, 2025, 8:00 AM EDT - 7 months ago

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Erasca to Present at Upcoming Investor Conferences in June

May 29, 2025, 8:00 AM EDT - 7 months ago

Erasca to Present at Upcoming Investor Conferences in June

Erasca Reports First Quarter 2025 Business Updates and Financial Results

May 13, 2025, 4:05 PM EDT - 8 months ago

Erasca Reports First Quarter 2025 Business Updates and Financial Results

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 13, 2025, 8:00 AM EDT - 8 months ago

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

Erasca to Present at the Bank of America Securities Health Care Conference

May 7, 2025, 8:00 AM EDT - 8 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Apr 29, 2025, 4:05 PM EDT - 8 months ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25, 2025, 11:33 AM EDT - 8 months ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 9 months ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Mar 20, 2025, 4:01 PM EDT - 9 months ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 11 months ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27, 2025, 12:09 AM EST - 11 months ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences

Nov 5, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 21, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:02 PM EDT - 1 year ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 16, 2024, 8:00 PM EDT - 1 year ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 8, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Erasca to Present at the Bank of America Health Care Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Erasca to Present at the Bank of America Health Care Conference

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Mar 29, 2024, 11:11 AM EDT - 1 year ago

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 8:30 PM EDT - 1 year ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Dec 11, 2023, 8:00 AM EST - 2 years ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 28, 2023, 8:00 AM EST - 2 years ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 9, 2023, 4:01 PM EST - 2 years ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Erasca to Present at Upcoming Investor Conferences in November

Nov 8, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at Upcoming Investor Conferences in November

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Aug 28, 2023, 6:05 AM EDT - 2 years ago

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

AMGN BLUE CAT CSCO CVX DOW IBM

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

Aug 14, 2023, 3:22 PM EDT - 2 years ago

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

CVX PUMP

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Jun 22, 2023, 4:01 PM EDT - 2 years ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Jun 5, 2023, 4:01 PM EDT - 2 years ago

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 31, 2023, 8:00 AM EDT - 2 years ago

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

Erasca Further Strengthens Business Leadership with Two Key Promotions

May 16, 2023, 8:00 AM EDT - 2 years ago

Erasca Further Strengthens Business Leadership with Two Key Promotions

Erasca Reports First Quarter 2023 Financial Results and Business Updates

May 15, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports First Quarter 2023 Financial Results and Business Updates

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

May 2, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

May 1, 2023, 8:00 AM EDT - 2 years ago

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

Apr 18, 2023, 9:00 AM EDT - 2 years ago

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

1SwingSensei
1SwingSensei Dec. 22 at 3:51 PM
$ERAS I'm liking the melt up of several stocks
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 17 at 11:35 PM
$ASNS $BEAT $ERAS $TLRY $18-$20 coming for TLRY… The Good News is I rarely miss!!
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 17 at 9:44 PM
$ASNS banked $ERAS Banking $BEAT Banked $TLRY Loaded… Avg $10.75, this is setting up for a major rally.. weak hands are out! PT $18-$20
0 · Reply
TravisA9
TravisA9 Dec. 17 at 6:06 PM
$ERAS Got back in a few weeks ago around $3.20 with some size. Clear breakout. I think we close gap from 12/2022, let’s see.
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 16 at 2:58 PM
$BDRX NHOD will send this to $9… Watching closely $ERAS looking good…. over $3.80 and we see mid $4’s
0 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 15 at 7:52 PM
$ERAS Adding more here… Beautiful swing set up!!!
1 · Reply
OvernightSwingKing
OvernightSwingKing Dec. 15 at 4:05 PM
$ERAS I’m in for a swing… PT1 $4.50
0 · Reply
prominence687
prominence687 Dec. 15 at 1:52 PM
$ERAS is looking primed!
0 · Reply
DavyDaveCharts
DavyDaveCharts Dec. 14 at 8:35 PM
$ERAS peekaboo
0 · Reply
vu_jade
vu_jade Dec. 13 at 10:21 PM
$ERAS yup
0 · Reply
sasanalyst
sasanalyst Dec. 12 at 9:46 PM
$ERAS
0 · Reply
bassman4444
bassman4444 Dec. 12 at 3:28 PM
$ERAS New here, What are the catalysts here for 12/25-1/26? Any thoughts appreciated!
2 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 5:28 PM
Mizuho updates rating for Erasca ( $ERAS ) to Outperform, target set at 4 → 5.
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 9 at 4:41 AM
$NUVL $ERAS $DKS $CRDF $ALGT
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 8 at 9:37 PM
piddly guaranteed targets: $INV $6.32+ $NUVB $10.24+ $NUVL $125.02+ $CCCC $2.91+ $ERAS $3.72+
0 · Reply
DavyDaveCharts
DavyDaveCharts Dec. 8 at 7:41 PM
$ERAS weekly: looks set for a move to 6.20 in the coming weeks.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 12:06 PM
$ERAS Share Price: $3.30 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.99 – $1.23 Target Zone: $1.81 – $2.21 Potential Upside: 72% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 3 at 10:28 PM
$PHVS $CCCC $GOSS $ERAS some newbs
0 · Reply
www_larval_com
www_larval_com Nov. 19 at 3:47 PM
$ERAS has turned -4% lower to 1% (~816Kv) a moment ago, 11/21 options, follow for more volatility.
1 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 2:19 PM
Guggenheim has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 3 → 5.
0 · Reply
Investor6
Investor6 Nov. 13 at 2:27 PM
$ERAS Erasca press release (ERAS): Q3 GAAP EPS of -$0.11 in-line. Cash, cash equivalents, and marketable securities were $362.4 million as of September 30, 2025, compared to $440.5 million as of December 31, 2024. Erasca expects its cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2028.
0 · Reply
RunnerSignals
RunnerSignals Nov. 12 at 9:23 PM
Market Warriors on the Move! $CNTA $TRX.X $ERAS $RANI $CHGG started down but closed strong
0 · Reply